Neoadjuvant Chemotherapy with Capecitabine and Temozolomide for Unresectable Pancreatic Neuroendocrine Tumor

por Devata, Sumana, Kim, Edward J.
Publicado 2012

Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders

por Phillips, Tycel, Devata, Sumana, Wilcox, Ryan A.
Publicado 2016

Detection of amyloid in abdominal fat pad aspirates in early amyloidosis: Role of electron microscopy and Congo red stained cell block sections

por Devata, Sumana, Hari, Parameswaran, Markelova, Natalia, Li, Rongshan, Komorowski, Richard, Shidham, Vinod B.
Publicado 2011

Performing and Processing FNA of Anterior Fat Pad for Amyloid

por Shidham, Vinod B., Hunt, Bryan, Jaradeh, Safwan S., Barboi, Alexandru C., Devata, Sumana, Hari, Parameswaran
Publicado 2010

Evaluating Acalabrutinib In The Treatment Of Mantle Cell Lymphoma: Design, Development, And Place In Therapy

por Girard, Jennifer, Reneau, John, Devata, Sumana, Wilcox, Ryan A, Kaminski, Mark S, Mercer, Jessica, Carty, Shannon, Phillips, Tycel J
Publicado 2019

P1082: RESULTS FROM A PHASE 1/2 STUDY OF TANDEM, BISPECIFIC ANTI-CD20/ANTI-CD19 (LV20.19) CAR T-CELLS FOR MANTLE CELL LYMPHOMA

por Shah, Nirav N, Fenske, Timothy, Johnson, Bryon, Szabo, Aniko, Devata, Sumana, Longo, Walter, Kearl, Tyce, Zamora, Anthony, Hari, Parameswaran, Schneider, Dina, Hamadani, Mehdi
Publicado 2023

Socioeconomic disadvantage contributes to ethnic disparities in multiple myeloma survival: a matched cohort study

por Buradagunta, Christopher Staffi, Garacci, Zhuping, D’Souza, Anita, Dhakal, Binod, Devata, Sumana, Janz, Siegfried, Thrift, Aaron P., Hari, Parameswaran, Stolley, Melinda, Dong, Jing
Publicado 2022

Use of GMI‐1271, an E‐selectin antagonist, in healthy subjects and in 2 patients with calf vein thrombosis

por Devata, Sumana, Angelini, Dana E., Blackburn, Susan, Hawley, Angela, Myers, Daniel D., Schaefer, Jordan K., Hemmer, Martina, Magnani, John L., Thackray, Helen M., Wakefield, Thomas W., Sood, Suman L.
Publicado 2020

Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas

por Murga-Zamalloa, Carlos, Polk, Avery, Hanel, Walter, Chowdhury, Pinki, Brown, Noah, Hristov, Alexandra C., Bailey, Nathanael G., Wang, Tianjiao, Phillips, Tycel, Devata, Sumana, Poonnen, Pradeep, Gomez-Gelvez, Juan, Inamdar, Kedar V., Wilcox, Ryan A.
Publicado 2017

Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma

por Huen, Auris, Haverkos, Bradley M., Zain, Jasmine, Radhakrishnan, Ramchandren, Lechowicz, Mary Jo, Devata, Sumana, Korman, Neil J., Pinter-Brown, Lauren, Oki, Yasuhiro, Barde, Prajak J., Nair, Ajit, Routhu, Kasi Viswanath, Viswanadha, Srikant, Vakkalanka, Swaroop, Iyer, Swaminathan P.
Publicado 2020

S224: HIGH COMPLETE RESPONSE RATE WITH TNB-486, A NOVEL CD19XCD3 T-CELL ENGAGER, IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: INTERIM RESULTS FROM AN ONGOING PHASE 1 STUDY

por Jacobs, Ryan, Nair, Ranjit, Cho, Seok-Goo, Devata, Sumana, Gaballa, Sameh, Yoon, Dok Hyun, Stevens, Don, Kim, Jin Seok, Shah, Nirav N, Brennan, Denise Marie, Law, Jason, Lesley, Robin, Chen, Rob, Forcina, Alessandra, Buelow, Ben, Hou, Jing-Zhou
Publicado 2023